Lavomax tab n / 125mg of 3 pieces

Description

Composition
Active substance:
Tilorona dihydrochloride – 125 mg ;.
Excipients:
Magnesium hydroxycarbonate pentahydrate – 69 mg, povidone – 4 mg of calcium stearate – 2 mg; shell – Sucrose – 158.2 mg Povidone – 5.56 mg, copovidone – 0.44 mg magnesium hydroxycarbonate pentahydrate – 25.7 mg Titanium dioxide – 1.2 mg colloidal silicon dioxide (Aerosil A-380) – 1 mg dye tropeolin-O – 0.1 mg macrogol 6000 – 6 mg, beeswax – 0.15 mg, paraffin liquid – 0.15 mg talc – 1.5 mg.
Description:
Tablets, coated tablets, from yellow to orange in color, circular shape. The core of an orange pill.
Product form:
Coated tablets, 125 mg.
3, 4, 6 or 10 tablets in blisters. One or two blisters together with instructions for medical use of the drug is placed in a cardboard pack.
Contraindications
Hypersensitivity to the drug.
During pregnancy and lactation.
Children’s age (18 years).
Deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (preparation contains sucrose).
Dosage
125 mg
Indications
In adults:
in the complex therapy of viral hepatitis A, B, C; in the complex therapy of HSV infection, cytomegalovirus infection; in the complex therapy of infectious-allergic and viral encephalomyelitis; in the complex therapy of urogenital and respiratory chlamydia, in the treatment of non-gonococcal urethritis, in the treatment of pulmonary tuberculosis; treatment and prevention of influenza and other acute respiratory viral infections.
Interaction with other drugs
Compatible with the means and standard antibiotic therapy of viral and bacterial diseases.
No clinically significant interaction with Lavomaksa® antibiotic agents standard therapy of viral and bacterial diseases, alcohol is not detected.
Overdose
Overdose cases Lavomaksa® unknown.
pharmachologic effect
Pharmacological group:
Antiviral immunostimulatory agent – interferon inducer of education.
Pharmacodynamics:
Tilorona stimulates the body’s production of alpha-, beta- and gamma-interferon. Major producers of interferon in response to tilorona are intestinal epithelial cells, hepatocytes, T-lymphocytes, and neutrophils. After ingestion maximum production of interferon is defined in a sequence – intestines – liver -. Bled 4-24 hours tilorona possesses immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, enhances antibody production, reduces the degree of immunosuppression, restores ratio of T-helpers / T-suppressors. It is effective against a variety of viral infections, including influenza virus, and other acute respiratory viral infections, hepatitis viruses, herpes viruses, cytomegalovirus and neurotropic viruses. antiviral mechanism of action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppressed reproduction of viruses.
Pharmacokinetics:
After ingestion tilorona rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% tilorona bound to plasma proteins. Tilorona displayed virtually unchanged in the feces (70%) and urine (9%). The half-life is 48 hours. Tilorona no biotransformation and does not accumulate in the body.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions, dyspepsia, intermittent fever.
special instructions
Use of the drug has no effect on ability to drive and engage in other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
The drug is taken orally, after meals.
For the treatment of viral hepatitis A – on the first day of 125 mg 2 times, then 125 mg every other day. Heading dose of 1.25 g (per course of treatment – 10 tablets of 125 mg).
For the treatment of acute hepatitis B – the first and second days of 125 mg, then 125 mg every other day. Heading dose of 2 g (per course of treatment – 16 125 mg tablets), with a protracted course of hepatitis B – 125 mg 2 times a day on the first day, followed by 125 mg every other day. Course dose 2.5 g (per course of treatment – 20 tablets of 125 mg).
In chronic hepatitis B – initial phase of treatment (2.5 g) – the first two days of 250 mg, then 125 mg every other day. The continuation phase (from 1.25 g to 2.5 g) – 125 mg per week. Heading dose Lavomaksa® from 3.75 to 5 g (in treatment – from 30 to 40 tablets of 125 mg), the duration of therapy of 3.5 – 6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process. In acute hepatitis C – the first and second days of 125 mg, then 125 mg every other day. Course dose 2.5 g (per course of treatment – 20 tablets of 125 mg).
In chronic hepatitis C – the initial phase of treatment (2.5 g) – the first two days of 250 mg, then 125 mg every other day. The continuation phase (2.5 g) – 125 mg per week. Heading dose Lavomaksa® – 5 g (per course of treatment – 40 tablets of 125 mg), the duration of treatment – 6 months, depending on the results of biochemical, immunological, morphological markers process activity.
In the treatment of influenza and other acute respiratory viral infections – in the first two days of illness of 125 mg, followed by 125 mg daily. Course dose of 750 mg (per course of treatment – 6 tablets of 125 mg).
For prevention of influenza and other acute respiratory viral infections – 125 mg once a week for 6 weeks (per course of treatment – 6 tablets of 125 mg).
For the treatment of herpes, cytomegalovirus infection – the first two days of 125 mg, followed by 125 mg daily. Course dose 2.5 g (per course of treatment – 20 tablets of 125 mg).
Urogenital and respiratory chlamydia, non-gonococcal urethritis – the first two days of 125 mg, followed by 125 mg daily. Heading dose of 1.25 g (per course of treatment – 10 tablets of 125 mg).
In the complex treatment of pulmonary tuberculosis – the first two days of 250 mg, then 125 mg every other day. Course dose 2.5 g (per course of treatment – 20 tablets of 125 mg).
In the complex treatment of infectious-allergic and viral encephalomyelitis dose set individually, the course of treatment is 4 weeks.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist